Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to gather efficacy data concerning overall survival with
electromagnetic fields when compared to a placebo amplitude-modulated radiofrequency
electromagnetic field device in subjects who have failed or are intolerant to at least two
previous systemic therapies.